Pharma-Bio Serv, Inc. (PBSV)

Inozyme Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is November - October.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 30, 2025	Oct 31, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021	Oct 31, 2020
Net Income	-0.19	-0.78	1.31	1.01	-2.09	2.05
Depreciation & Amortization	0.2	0.18	0.19	0.19	0.07	0.09
Loss (Gain) From Sale of Assets	-	-	-	-	-0.01	-0.01
Stock-Based Compensation	0.04	0.05	0.05	0.07	0.06	0.04
Provision & Write-off of Bad Debts	-	-	-	-	5.25	-
Other Operating Activities	-0.14	-0.25	-0.32	-	-1.96	-
Change in Accounts Receivable	-0.02	1.46	1.09	-0.46	-0.13	-0.94
Change in Other Net Operating Assets	-1.22	-1.23	-0.43	-0.21	-0.38	0.29
Operating Cash Flow	-1.32	-0.57	1.89	0.59	0.8	1.51
Operating Cash Flow Growth	-	-	219.17%	-26.39%	-46.85%	-
Capital Expenditures	-0.16	-0.16	-0.01	-0.02	-0.01	-0.06
Sale of Property, Plant & Equipment	-	-	-	-	0.06	0.03
Investment in Securities	1.79	-1.2	-4.21	-	-	-
Other Investing Activities	-	-	-	-	1.25	-
Investing Cash Flow	1.62	-1.36	-4.22	-0.02	1.3	-0.03
Long-Term Debt Issued	-	-	-	-	-	1.93
Net Debt Issued (Repaid)	-	-	-	-	-	1.93
Repurchase of Common Stock	-0.02	-0.01	-0.03	-0.08	-0.03	-0
Common Dividends Paid	-1.72	-1.72	-1.72	-3.45	-1.73	-1.73
Financing Cash Flow	-1.74	-1.73	-1.76	-3.53	-1.75	0.2
Foreign Exchange Rate Adjustments	0.02	-0.02	0.07	-0.05	-0.02	-0.04
Net Cash Flow	-1.42	-3.68	-4.02	-3.01	0.33	1.65
Free Cash Flow	-1.49	-0.73	1.88	0.57	0.79	1.46
Free Cash Flow Growth	-	-	228.64%	-27.81%	-45.57%	-
Free Cash Flow Margin	-15.42%	-7.64%	11.10%	2.96%	3.95%	6.77%
Free Cash Flow Per Share	-0.07	-0.03	0.08	0.03	0.03	0.06
Cash Interest Paid	-	-	-	-	0	0
Cash Income Tax Paid	0.76	0.66	0.42	0.21	0.57	0.21
Levered Free Cash Flow	-0.72	0.46	2.02	0.28	4	-0.81
Unlevered Free Cash Flow	-0.72	0.46	2.02	0.28	4	-0.81
Change in Net Working Capital	0.34	-1.19	-1.09	0.7	-6.29	2.28

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.